Document is current
Any future updates will be listed below
-
Authors
Fahrmann, Johannes F.
Ghasemi, Seyyed Mahmood
Han, Chae Y.
Wu, Ranran
Dennison, Jennifer B.
Vykoukal, Jody
Celestino, Joseph
Lu, Karen
Lu, Zhen
Drescher, Charles
Do, Kim-Anh
Hanash, Samir
Bast, Robert C.
Irajizad, Ehsan
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 31 July 2024
First Online: 28 August 2024
Declarations
:
: The study is a retrospective analysis of blood specimens that were obtained preoperatively with informed consent under IRB/ethical committees approved protocols at the University of Texas M.D. Anderson Cancer Center (MDACC, LAB04-0687) and at the Fred Hutchinson Cancer Research Center (FHCRC, IRB 4563) []. Control plasma were obtained from women who did not develop cancer while participating in the Normal Risk Ovarian Screening Study (NROSS) trial coordinated by MDACC [] or were healthy donors at the FHCC under improved IRB protocols.
: Not applicable.
: Dr. Bast receives royalties from Fujirebio Diagnostics, Inc, for the discovery of CA125.
